EHDN statement on the discontinuation of the GENERATION HD1 trial

On Monday 22 March 2021 Roche announced that dosing is being permanently discontinued in the GENERATION HD1 phase III trial evaluating the effect of tominersen, an ASO-based huntingtin lowering drug on the clinical course of HD. Dosing is also being paused on the open label extension study, GEN-EXTEND. This decision is the outcome of a […]

Weiterlesen…